Tag: Medtronic

Medtronic Congenital Heart Disease Studies Show Strong 10-Year Performance for Melody Transcatheter Pulmonary Valve and Primary Results from the Harmony Pivotal Trial

Milestone Results Presented as Late-Breaking Clinical Science at SCAI 2020 DUBLIN, May 15, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced results from two late-breaking clinical trials presented virtually at the 2020 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific […]

Jeffrey J. Popma, M.D. to Join Medtronic as Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart Businesses

DUBLIN, May 18, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced Jeffrey J. Popma, M.D., professor of medicine at Harvard Medical School and director of interventional cardiology at Beth Israel Deaconess Medical Center in Boston, […]

Medtronic Evolut TAVR System Demonstrates Excellent Outcomes in Study of Low-Risk Patients with Bicuspid Aortic Stenosis

ACC.20/WCC: Low Rates of Paravalvular Leak and High Survival Observed in Late-breaking Clinical Trial of Low-Risk Bicuspid Aortic Stenosis Patients DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced late-breaking clinical data from […]

Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure

ACC.20/WCC: Study Finds Significant Blood Pressure Reductions Achieved with RDN in Absence of Anti-Hypertensive Medication  Medtronic Receives FDA “Breakthrough Device Designation” for Symplicity Spyral™ Renal Denervation System DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT), the global leader in medical technology, […]

Medtronic Begins New Pilot Study as Part of SPYRAL HTN Clinical Program for Renal Denervation in Hypertension Patients

SPYRAL DYSTAL Study to Evaluate the Effects of RDN Using Fewer, Targeted Ablations to Achieve Meaningful Blood Pressure Reductions DUBLIN, Feb. 04, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT) today announced it will begin enrollment in a pilot study evaluating the safety […]

Medtronic Receives CE Mark for Cobalt™ and Crome™ Portfolio of BlueSync™-Enabled Implantable Defibrillators, Cardiac Resynchronization Therapy-Defibrillators

Next Generation Technology Includes Features that Automatically Adjust to Patient Needs, and Offers Physicians Heart Failure Diagnostic Insights DUBLIN, Jan. 30, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT) today announced it has received CE (Conformité Européenne) Mark for its Cobalt™ and […]